Record Information |
---|
Version | 2.0 |
---|
Created at | 2006-05-18 08:53:59 UTC |
---|
Updated at | 2024-09-03 04:22:32 UTC |
---|
NP-MRD ID | NP0000237 |
---|
Natural Product DOI | https://doi.org/10.57994/2894 |
---|
Secondary Accession Numbers | None |
---|
Natural Product Identification |
---|
Common Name | Nicotine |
---|
Description | Nicotine is an alkaloid found in the nightshade family of plants (Solanaceae), predominantly in tobacco and in lower quantities in tomato, potato, eggplant (aubergine), and green pepper. Nicotine alkaloids are also found in the leaves of the coca plant. Nicotine constitutes 0.3 To 5% of the tobacco plant by dry weight, with biosynthesis taking place in the root and accumulation in the leaves. It is a potent neurotoxin with particular specificity to insects; therefore nicotine was widely used as an insecticide in the past and nicotine derivatives such as imidacloprid continue to be widely used. It has been noted that the majority of people diagnosed with schizophrenia smoke tobacco. Estimates for the number of schizophrenics that smoke range from 75% to 90%. It was recently argued that the increased level of smoking in schizophrenia may be due to a desire to self-medicate with nicotine. More recent research has found the reverse: It is a risk factor without long-term benefit, used only for its short-term effects. However, research on nicotine as administered through a patch or gum is ongoing. As nicotine enters the body, it is distributed quickly through the bloodstream and can cross the blood-brain barrier. On average, it takes about seven seconds for the substance to reach the brain. The half-life of nicotine in the body is around 2 hours. The amount of nicotine inhaled with tobacco smoke is a fraction of the amount contained in the tobacco leaves (most of the substance is destroyed by the heat). The amount of nicotine absorbed by the body from smoking depends on many factors, including the type of tobacco, whether the smoke is inhaled, and whether a filter is used. For chewing tobacco, often called dip, snuff, or sinus, which is held in the mouth between the lip and gum, the amount released into the body tends to be much greater than smoked tobacco. The currently available literature indicates that nicotine, on its own, does not promote the development of cancer in healthy tissue and has no mutagenic properties. Its teratogenic properties have not yet been adequately researched, and while the likelihood of birth defects caused by nicotine is believed to be very small or nonexistent, nicotine replacement product manufacturers recommend consultation with a physician before using a nicotine patch or nicotine gum while pregnant or nursing. However, nicotine and the increased acetylcholinic activity it causes have been shown to impede apoptosis, which is one of the methods by which the body destroys unwanted cells (programmed cell death). Since apoptosis helps to remove mutated or damaged cells that may eventually become cancerous, the inhibitory actions of nicotine create a more favourable environment for cancer to develop. Thus, nicotine plays an indirect role in carcinogenesis. It is also important to note that its addictive properties are often the primary motivating factor for tobacco smoking, contributing to the proliferation of cancer. Nicotine is a highly toxic alkaloid. It is the prototypical agonist at nicotinic cholinergic receptors where it dramatically stimulates neurons and ultimately blocks synaptic transmission. Nicotine is also important medically because of its presence in tobacco smoke. Nicotine is a hygroscopic, oily liquid that is miscible with water in its base form. As a nitrogenous base, nicotine forms salts with acids that are usually solid and water soluble. Nicotine easily penetrates the skin. As shown by the physical data, free base nicotine will burn at a temperature below its boiling point, and its vapours will combust at 95 °C in the air despite a low vapour pressure. Because of this, most nicotine is burned when a cigarette is smoked; however, enough is inhaled to provide the desired effects. Nicotine is a stimulant drug that acts as an agonist at nicotinic acetylcholine receptors. These are ionotropic receptors composed of five homomeric or heteromeric subunits. In the brain, nicotine binds to nicotinic acetylcholine receptors on dopaminergic neurons in the cortico-limbic pathways. This causes the channel to open and allow conductance of multiple cations including sodium, calcium, and potassium. This leads to depolarization, which activates voltage-gated calcium channels and allows more calcium to enter the axon terminal. Calcium stimulates vesicle trafficking towards the plasma membrane and the release of dopamine into the synapse. Dopamine binding to its receptors is responsible for the euphoric and addictive properties of nicotine. Nicotine also binds to nicotinic acetylcholine receptors on the chromaffin cells in the adrenal medulla. Binding opens the ion channel allowing an influx of sodium which causes depolarization of the cell and activates voltage-gated calcium channels. Calcium triggers the release of epinephrine from intracellular vesicles into the bloodstream, which causes vasoconstriction, increased blood pressure, increased heart rate, and increased blood sugar. Cotinine is a byproduct of the metabolism of nicotine which remains in the blood for up to 48 hours and can be used as an indicator of a person's exposure to smoke. In high doses, nicotine will cause a blocking of the nicotinic acetylcholine receptor, which is the reason for its toxicity and its effectiveness as an insecticide. In lower concentrations, the substance acts as a stimulant in mammals and is one of the main factors responsible for the dependence-forming and energy-boosting properties of tobacco smoking. |
---|
Structure | InChI=1S/C10H14N2/c1-12-7-3-5-10(12)9-4-2-6-11-8-9/h2,4,6,8,10H,3,5,7H2,1H3/t10-/m0/s1 |
---|
Synonyms | Value | Source |
---|
(-)-Nicotine | ChEBI | (-)-3-(1-Methyl-2-pyrrolidyl)pyridine | ChEBI | (-)-3-(N-Methylpyrrolidino)pyridine | ChEBI | (R)-3-(1-Methyl-2-pyrrolidinyl)pyridine | ChEBI | (S)-(-)-Nicotine | ChEBI | (S)-3-(1-Methylpyrrolidin-2-yl)pyridine | ChEBI | (S)-3-(N-Methylpyrrolidin-2-yl)pyridine | ChEBI | 1-Methyl-2-(3-pyridyl)pyrrolidine | ChEBI | 3-(1-Methyl-2-pyrollidinyl)pyridine | ChEBI | 3-(1-Methylpyrrolidin-2-yl)pyridine | ChEBI | 3-(2-(N-Methylpyrrolidinyl))pyridine | ChEBI | 3-(N-Methylpyrollidino)pyridine | ChEBI | L(-)-Nicotine | ChEBI | L-3-(1-Methyl-2-pyrrolidyl)pyridine | ChEBI | L-Nicotine | ChEBI | (S)-Nicotine | Kegg | Habitrol | Kegg | (+)-Nicotine | HMDB | (R,S)-Nicotine | HMDB | 1-Methyl-2-(3-pyridal)-pyrrolidene | HMDB | 1-Methyl-2-(3-pyridal)-pyrrolidine | HMDB | 1-Methyl-2-(3-pyridiyl)pyrrolidine | HMDB | 2'-beta-H-Nicotine | HMDB | 3-(1-Methyl-2-pyrrolidinyl)-pyridine | HMDB | 3-(1-Methyl-2-pyrrolidinyl)pyridine | HMDB | 3-(N-Methylpyrrolidino)pyridine | HMDB | 3-N-Methylpyrrolidine | HMDB | a -N-Methylpyrrolidine | HMDB | a-N-Methylpyrrolidine | HMDB | alpha-N-Methylpyrrolidine | HMDB | beta-Pyridyl-alpha-N-methylpyrrolidine | HMDB | D-Nicotine | HMDB | delta-Nicotine | HMDB | Destruxol | HMDB | DL-Tetrahydronicotyrine | HMDB | Fumeto bac | HMDB | Methyl-2-pyrrolidinyl)pyridine | HMDB | Nicoderm | HMDB | Nicotine polacrilex | HMDB | R)-(+)-Nicotine | HMDB | Tartrate, nicotine | HMDB | Nicotine bitartrate | HMDB | Nicotine tartrate | HMDB | Bitartrate, nicotine | HMDB | Nicotine | ChEBI |
|
---|
Chemical Formula | C10H14N2 |
---|
Average Mass | 162.2316 Da |
---|
Monoisotopic Mass | 162.11570 Da |
---|
IUPAC Name | 3-[(2S)-1-methylpyrrolidin-2-yl]pyridine |
---|
Traditional Name | nicoderm CQ |
---|
CAS Registry Number | 54-11-5 |
---|
SMILES | [H][C@]1(CCCN1C)C1=CC=CN=C1 |
---|
InChI Identifier | InChI=1S/C10H14N2/c1-12-7-3-5-10(12)9-4-2-6-11-8-9/h2,4,6,8,10H,3,5,7H2,1H3/t10-/m0/s1 |
---|
InChI Key | SNICXCGAKADSCV-JTQLQIEISA-N |
---|
Experimental Spectra |
---|
|
| Spectrum Type | Description | Depositor Email | Depositor Organization | Depositor | Deposition Date | View |
---|
HSQC NMR | [1H, 13C] NMR Spectrum (2D, 600 MHz, CDCl3, experimental) | bgnzk@missouri.edu | Sumner Lab, MU Metabolomics Center, University of Missouri, Columbia. MO, USA | Dr. Bharat Goel | 2024-06-21 | View Spectrum | HMBC NMR | [1H, 13C] NMR Spectrum (2D, 600 MHz, CDCl3, experimental) | bgnzk@missouri.edu | Sumner Lab, MU Metabolomics Center, University of Missouri, Columbia. MO, USA | Dr. Bharat Goel | 2024-06-21 | View Spectrum | COSY NMR | [1H, 1H] NMR Spectrum (2D, 600 MHz, CDCl3, experimental) | bgnzk@missouri.edu | Sumner Lab, MU Metabolomics Center, University of Missouri, Columbia. MO, USA | Dr. Bharat Goel | 2024-06-21 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 201 MHz, CDCl3, experimental) | bgnzk@missouri.edu | Sumner Lab, MU Metabolomics Center, University of Missouri, Columbia. MO, USA | Dr. Bharat Goel | 2024-06-21 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 600 MHz, CDCl3, experimental) | bgnzk@missouri.edu | Sumner Lab, MU Metabolomics Center, University of Missouri, Columbia. MO, USA | Dr. Bharat Goel | 2024-06-21 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 600 MHz, H2O, experimental) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 400 MHz, D2O, simulated) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 400 MHz, D2O, simulated) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 400 MHz, D2O, simulated) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 400 MHz, D2O, experimental) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 2D NMR | [1H, 13C]-HSQC NMR Spectrum (2D, 600 MHz, H2O, experimental) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum |
| Predicted Spectra |
---|
|
| Spectrum Type | Description | Depositor ID | Depositor Organization | Depositor | Deposition Date | View |
---|
| Chemical Shift Submissions |
---|
|
| Spectrum Type | Description | Depositor Email | Depositor Organization | Depositor | Deposition Date | View |
---|
1D NMR | 1H NMR Spectrum (1D, 600, CDCl3, simulated) | bgnzk@missouri.edu | Sumner Lab, MU Metabolomics Center, University of Missouri, Columbia. MO, USA | Dr. Bharat Goel | 2024-06-21 | View Spectrum |
| Species |
---|
Species of Origin | |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as pyrrolidinylpyridines. Pyrrolidinylpyridines are compounds containing a pyrrolidinylpyridine ring system, which consists of a pyrrolidine ring linked to a pyridine ring. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organoheterocyclic compounds |
---|
Class | Pyridines and derivatives |
---|
Sub Class | Pyrrolidinylpyridines |
---|
Direct Parent | Pyrrolidinylpyridines |
---|
Alternative Parents | |
---|
Substituents | - Pyrrolidinylpyridine
- Alkaloid or derivatives
- Aralkylamine
- N-alkylpyrrolidine
- Heteroaromatic compound
- Pyrrolidine
- Tertiary aliphatic amine
- Tertiary amine
- Azacycle
- Organic nitrogen compound
- Organopnictogen compound
- Hydrocarbon derivative
- Organonitrogen compound
- Amine
- Aromatic heteromonocyclic compound
|
---|
Molecular Framework | Aromatic heteromonocyclic compounds |
---|
External Descriptors | |
---|
Physical Properties |
---|
State | Liquid |
---|
Experimental Properties | Property | Value | Reference |
---|
Melting Point | -79 °C | Not Available | Boiling Point | 247.00 °C. @ 760.00 mm Hg | The Good Scents Company Information System | Water Solubility | 1000 mg/mL | Not Available | LogP | 1.17 | Hansch CH, Leo A and Hoekman DH. "Exploring QSAR: Hydrophobic, Electronic, and Steric Constraints. Volume 1" ACS Publications (1995). |
|
---|
Predicted Properties | |
---|
General References | - Hayslett RL, Tizabi Y: Effects of donepezil, nicotine and haloperidol on the central serotonergic system in mice: implications for Tourette's syndrome. Pharmacol Biochem Behav. 2005 Aug;81(4):879-86. [PubMed:16045972 ]
- Henningfield JE, Radzius A, Cooper TM, Clayton RR: Drinking coffee and carbonated beverages blocks absorption of nicotine from nicotine polacrilex gum. JAMA. 1990 Sep 26;264(12):1560-4. [PubMed:2395197 ]
- Hrnciar J, Katreniakova M, Lepej J, Okapcova J: [The effects of nicotine on leptin levels in patients with android obesity]. Vnitr Lek. 1997 Sep;43(9):562-5. [PubMed:9750463 ]
- LeSage MG, Keyler DE, Pentel PR: Current status of immunologic approaches to treating tobacco dependence: vaccines and nicotine-specific antibodies. AAPS J. 2006 Feb 24;8(1):E65-75. [PubMed:16584135 ]
- Terry AV Jr, Hernandez CM, Hohnadel EJ, Bouchard KP, Buccafusco JJ: Cotinine, a neuroactive metabolite of nicotine: potential for treating disorders of impaired cognition. CNS Drug Rev. 2005 Autumn;11(3):229-52. [PubMed:16389292 ]
- Marchei E, Durgbanshi A, Rossi S, Garcia-Algar O, Zuccaro P, Pichini S: Determination of arecoline (areca nut alkaloid) and nicotine in hair by high-performance liquid chromatography/electrospray quadrupole mass spectrometry. Rapid Commun Mass Spectrom. 2005;19(22):3416-8. [PubMed:16259042 ]
- Maurer P, Jennings GT, Willers J, Rohner F, Lindman Y, Roubicek K, Renner WA, Muller P, Bachmann MF: A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity. Eur J Immunol. 2005 Jul;35(7):2031-40. [PubMed:15971275 ]
- Warner DO, Joyner MJ, Charkoudian N: Nicotine increases initial blood flow responses to local heating of human non-glabrous skin. J Physiol. 2004 Sep 15;559(Pt 3):975-84. Epub 2004 Jul 22. [PubMed:15272048 ]
- Guthrie SK, Ni L, Zubieta JK, Teter CJ, Domino EF: Changes in craving for a cigarette and arterial nicotine plasma concentrations in abstinent smokers. Prog Neuropsychopharmacol Biol Psychiatry. 2004 Jul;28(4):617-23. [PubMed:15276686 ]
- Cerny T: Anti-nicotine vaccination: where are we? Recent Results Cancer Res. 2005;166:167-75. [PubMed:15648190 ]
- Nakazawa A, Shigeta M, Ozasa K: Smoking cigarettes of low nicotine yield does not reduce nicotine intake as expected: a study of nicotine dependency in Japanese males. BMC Public Health. 2004 Jul 20;4:28. [PubMed:15265231 ]
- Groner JA, Hoshaw-Woodard S, Koren G, Klein J, Castile R: Screening for children's exposure to environmental tobacco smoke in a pediatric primary care setting. Arch Pediatr Adolesc Med. 2005 May;159(5):450-5. [PubMed:15867119 ]
- Stepans MB, Wilhelm SL, Dolence K: Smoking hygiene: reducing infant exposure to tobacco. Biol Res Nurs. 2006 Oct;8(2):104-14. [PubMed:17003250 ]
- Moriya F, Hashimoto Y: Nicotine and cotinine levels in blood and urine from forensic autopsy cases. Leg Med (Tokyo). 2004 Jul;6(3):164-9. [PubMed:15231285 ]
- Chetiyanukornkul T, Toriba A, Kizu R, Kimura K, Hayakawa K: Hair analysis of nicotine and cotinine for evaluating tobacco smoke exposure by liquid chromatography-mass spectrometry. Biomed Chromatogr. 2004 Nov;18(9):655-61. [PubMed:15386502 ]
- Klein J, Blanchette P, Koren G: Assessing nicotine metabolism in pregnancy--a novel approach using hair analysis. Forensic Sci Int. 2004 Oct 29;145(2-3):191-4. [PubMed:15451092 ]
- Ingram JR, Routledge P, Rhodes J, Marshall RW, Buss DC, Evans BK, Feyerabend C, Thomas GA: Nicotine enemas for treatment of ulcerative colitis: a study of the pharmacokinetics and adverse events associated with three doses of nicotine. Aliment Pharmacol Ther. 2004 Oct 15;20(8):859-65. [PubMed:15479357 ]
- Fallon JH, Keator DB, Mbogori J, Taylor D, Potkin SG: Gender: a major determinant of brain response to nicotine. Int J Neuropsychopharmacol. 2005 Mar;8(1):17-26. Epub 2004 Dec 6. [PubMed:15579215 ]
- Metz-Favre C, Donnay C, de Blay F: [Markers of environmental tobacco smoke (ETS) exposure]. Rev Mal Respir. 2005 Feb;22(1 Pt 1):81-92. [PubMed:15968761 ]
- Fontaine B: [Smoking and breastfeeding: how can we help mothers stop smoking?]. J Gynecol Obstet Biol Reprod (Paris). 2005 Apr;34 Spec No 1:3S209-12. [PubMed:15980790 ]
- Dempsey D, Tutka P, Jacob P 3rd, Allen F, Schoedel K, Tyndale RF, Benowitz NL: Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clin Pharmacol Ther. 2004 Jul;76(1):64-72. [PubMed:15229465 ]
- Miksys S, Tyndale RF: Nicotine induces brain CYP enzymes: relevance to Parkinson's disease. J Neural Transm Suppl. 2006;(70):177-80. [PubMed:17017527 ]
- Katsura M, Ohkuma S: Functional proteins involved in regulation of intracellular Ca(2+) for drug development: chronic nicotine treatment upregulates L-type high voltage-gated calcium channels. J Pharmacol Sci. 2005 Mar;97(3):344-7. Epub 2005 Mar 12. [PubMed:15764844 ]
- Ziegler UE, Kauczok J, Dietz UA, Reith HB, Schmidt K: Clinical correlation between the consumption of nicotine and cotinine concentrations in urine and serum by competitive enzyme-linked immunosorbent assay. Pharmacology. 2004 Dec;72(4):254-9. [PubMed:15539886 ]
- Tanaka H, Tanabe N, Shoji M, Suzuki N, Katono T, Sato S, Motohashi M, Maeno M: Nicotine and lipopolysaccharide stimulate the formation of osteoclast-like cells by increasing macrophage colony-stimulating factor and prostaglandin E2 production by osteoblasts. Life Sci. 2006 Mar 6;78(15):1733-40. Epub 2005 Nov 2. [PubMed:16266722 ]
- Gutala R, Wang J, Hwang YY, Haq R, Li MD: Nicotine modulates expression of amyloid precursor protein and amyloid precursor-like protein 2 in mouse brain and in SH-SY5Y neuroblastoma cells. Brain Res. 2006 Jun 6;1093(1):12-9. Epub 2006 May 16. [PubMed:16707114 ]
- Tanabe J, Tregellas JR, Martin LF, Freedman R: Effects of nicotine on hippocampal and cingulate activity during smooth pursuit eye movement in schizophrenia. Biol Psychiatry. 2006 Apr 15;59(8):754-61. Epub 2005 Nov 2. [PubMed:16259965 ]
- Aguilar MC, Gurpegui M, Diaz FJ, de Leon J: Nicotine dependence and symptoms in schizophrenia: naturalistic study of complex interactions. Br J Psychiatry. 2005 Mar;186:215-21. [PubMed:15738502 ]
- Nolley EP, Kelley BM: Adolescent reward system perseveration due to nicotine: studies with methylphenidate. Neurotoxicol Teratol. 2007 Jan-Feb;29(1):47-56. Epub 2006 Oct 4. [PubMed:17129706 ]
|
---|